EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG

Objective: Eltrombopag is a small molecule thrombopoietin-receptor agonist used orally for the treatment.There is a high risk of thrombosis associated with the use of Eltrombopag. Our aim in this study is evaluating the incidence of arterial and venous thrombosis in patients using Eltrombopag and fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Derya Deniz Kurekci, Melda Isevi, Engin Kelkitli, Mehmet Turgut
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/2c39d1b1858b496d89a14717559a9c3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2c39d1b1858b496d89a14717559a9c3d
record_format	dspace
spelling	oai:doaj.org-article:2c39d1b1858b496d89a14717559a9c3d2021-11-10T04:38:13ZEVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG2531-137910.1016/j.htct.2021.10.1067https://doaj.org/article/2c39d1b1858b496d89a14717559a9c3d2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921012141https://doaj.org/toc/2531-1379Objective: Eltrombopag is a small molecule thrombopoietin-receptor agonist used orally for the treatment.There is a high risk of thrombosis associated with the use of Eltrombopag. Our aim in this study is evaluating the incidence of arterial and venous thrombosis in patients using Eltrombopag and followed up in our center with the diagnosis of ITP, MDS and aplastic anemia, and contributing to the literature with the data of Central Black Sea by retrospectively evaluating the predisposing factors. Methodology: In this study, the data of 144 patients who were treated with Eltrombopag with the diagnosis of ITP, MDS and aplastic anemia at Ondokuz Mayıs University Faculty of Medicine Hematology Clinic between 2009-2019 were analyzed retrospectively. The data of the patients were obtained retrospectively from the hospital management information system. Results: The study included 144 patients who treated with Eltrombopag. 66 (45.8%) of the patients were male and 78 (54.2%) were female. The mean age of the patients was 54.12 ± 20.08 years. 102 (70.8%) of the patient were diagnosed with ITP, 31 (21.5%) with aplastic anemia and 12 (7.6%) with MDS. Thrombosis was observed in 7 (4.9%) of 144 patients who treated with Eltrombopag. Venous thrombosis was found in 6 (4.2%) of these patients and arterial thrombosis was found in one patient (0.7%). Conclusion: Eltrombopag treatment poses a risk for thromboembolic events. The treatment process should be followed closely especially in patients with known risk factors for thrombosis.Derya Deniz KurekciMelda IseviEngin KelkitliMehmet TurgutElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S54- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Derya Deniz Kurekci Melda Isevi Engin Kelkitli Mehmet Turgut EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG
description	Objective: Eltrombopag is a small molecule thrombopoietin-receptor agonist used orally for the treatment.There is a high risk of thrombosis associated with the use of Eltrombopag. Our aim in this study is evaluating the incidence of arterial and venous thrombosis in patients using Eltrombopag and followed up in our center with the diagnosis of ITP, MDS and aplastic anemia, and contributing to the literature with the data of Central Black Sea by retrospectively evaluating the predisposing factors. Methodology: In this study, the data of 144 patients who were treated with Eltrombopag with the diagnosis of ITP, MDS and aplastic anemia at Ondokuz Mayıs University Faculty of Medicine Hematology Clinic between 2009-2019 were analyzed retrospectively. The data of the patients were obtained retrospectively from the hospital management information system. Results: The study included 144 patients who treated with Eltrombopag. 66 (45.8%) of the patients were male and 78 (54.2%) were female. The mean age of the patients was 54.12 ± 20.08 years. 102 (70.8%) of the patient were diagnosed with ITP, 31 (21.5%) with aplastic anemia and 12 (7.6%) with MDS. Thrombosis was observed in 7 (4.9%) of 144 patients who treated with Eltrombopag. Venous thrombosis was found in 6 (4.2%) of these patients and arterial thrombosis was found in one patient (0.7%). Conclusion: Eltrombopag treatment poses a risk for thromboembolic events. The treatment process should be followed closely especially in patients with known risk factors for thrombosis.
format	article
author	Derya Deniz Kurekci Melda Isevi Engin Kelkitli Mehmet Turgut
author_facet	Derya Deniz Kurekci Melda Isevi Engin Kelkitli Mehmet Turgut
author_sort	Derya Deniz Kurekci
title	EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG
title_short	EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG
title_full	EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG
title_fullStr	EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG
title_full_unstemmed	EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG
title_sort	evaluation of the frequency of arterial and venous thrombosis and predisposing factors in patients using eltrombopag
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/2c39d1b1858b496d89a14717559a9c3d
work_keys_str_mv	AT deryadenizkurekci evaluationofthefrequencyofarterialandvenousthrombosisandpredisposingfactorsinpatientsusingeltrombopag AT meldaisevi evaluationofthefrequencyofarterialandvenousthrombosisandpredisposingfactorsinpatientsusingeltrombopag AT enginkelkitli evaluationofthefrequencyofarterialandvenousthrombosisandpredisposingfactorsinpatientsusingeltrombopag AT mehmetturgut evaluationofthefrequencyofarterialandvenousthrombosisandpredisposingfactorsinpatientsusingeltrombopag
_version_	1718440539047591936

EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG

Ejemplares similares